We Offer Worldwide Shipping
Login Wishlist

Folic acid

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-F2004

  • Specification : 98%

  • CAS number : 59-30-3

  • Formula : C19H19N7O6

  • Molecular Weight : 441.4

  • PUBCHEM ID : 135398658

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-F2004

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

441.4

Appearance

Yellow crystalline powder

Botanical Source

herbs of Mangifera indica L.

Structure Type

Nucleosiede

Category

Standards;Natural Pytochemical;API

SMILES

C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N

Synonyms

glutamic acid, N-[4-[[(2-amino-4,8-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-/VM/PGA/Folbal/folic/FOLSAN/Folic acid/Folate/N-[p-[[(2-Amino-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic Acid/Fola/N-(p-[(2-Amino-4-hydroxypyrimido[4,5-b]pyrazin-6-yl)methylamino]benzoyl)glutamic Acid/pteroic acid-glutamate/Pteroyglutamic acid/Folsav/4-Pteridinol, 2-amino-6-((p-((1,3-dicarboxypropyl)carbamoyl)anilino)methyl)-/PGA/PTEGLU/N-(4-{[(2-Amino-4-oxo-4,8-dihydropteridin-6-yl)methyl]amino}benzoyl)glutamic acid/2-[(4-{[(2-Amino-4-oxo-1,4-dihydro-6-pteridinyl)methyl]amino}benzoyl)amino]pentanedioic acid/N-(4-{[(2-Amino-4-hydroxypteridin-6-yl)methyl]amino}benzoyl)glutamic acid/Aspol/N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)glutamic acid/Glutamic acid, N-[4-[[(2-amino-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-/N-(4-{[(2-Amino-4-oxo-1,4-dihydro-6-pteridinyl)methyl]amino}benzoyl)glutamic acid/Folicacidhydrate

IUPAC Name

(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid

Density

1.6±0.1 g/cm3

Solubility

Aqueous base; DMSO

Flash Point

Boiling Point

Melting Point

250 °C

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2936290000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:59-30-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

31996281

Abstract

Targeted drug delivery systems have currently demonstrated considerable potential clinical benefits in cancer treatment. Curcumin has become a candidate anti-tumor drug for the therapy of glioblastoma multiforme (GBM) by increasing cell apoptosis and suppressing cell proliferation. In current research, we explored a novel targeted drug delivery system with a self-assembly measure by curcumin, MPEG-PLA and Fa-PEG-PLA. Compared with free curcumin and Cur/MPEG-PLA, Cur/Fa-PEG-PLA can remarkably suppress the growth of GL261 cells and promote apoptotic rate. Moreover, after the procession of tumor-bearing mice with curcumin/Fa-PEG-PLA complex, tumor growth in subcutaneous and intracranial tumor models were repressed via suppressing angiogenesis and facilitating apoptosis in vivo. The Curcumin/Fa-PEG-PLA nanoparticle may be a novel drug for the therapy of GBM.

Title

Anti-Glioma Effect with Targeting Therapy Using Folate Modified Nano-Micelles Delivery Curcumin.

Author

He Y, Wu C, Duan J, Miao J, Ren H, Liu J.

Publish date

2020 Jan 1

PMID

31910279

Abstract

IMPORTANCE:
Dietary supplements marketed for male fertility commonly contain folic acid and zinc based on limited prior evidence for improving semen quality. However, no large-scale trial has examined the efficacy of this therapy for improving semen quality or live birth.

OBJECTIVE:
To determine the effect of daily folic acid and zinc supplementation on semen quality and live birth.

DESIGN, SETTING, AND PARTICIPANTS:
The Folic Acid and Zinc Supplementation Trial was a multicenter randomized clinical trial. Couples (n = 2370; men aged ≥18 years and women aged 18-45 years) planning infertility treatment were enrolled at 4 US reproductive endocrinology and infertility care study centers between June 2013 and December 2017. The last 6-month study visit for semen collection occurred during August 2018, with chart abstraction of live birth and pregnancy information completed during April 2019.

INTERVENTIONS:
Men were block randomized by study center and planned infertility treatment (in vitro fertilization, other treatment at a study site, and other treatment at an outside clinic) to receive either 5 mg of folic acid and 30 mg of elemental zinc (n = 1185) or placebo (n = 1185) daily for 6 months.

MAIN OUTCOMES AND MEASURES:
The co-primary outcomes were live birth (resulting from pregnancies occurring within 9 months of randomization) and semen quality parameters (sperm concentration, motility, morphology, volume, DNA fragmentation, and total motile sperm count) at 6 months after randomization.

RESULTS:
Among 2370 men who were randomized (mean age, 33 years), 1773 (75%) attended the final 6-month study visit. Live birth outcomes were available for all couples, and 1629 men (69%) had semen available for analysis at 6 months after randomization. Live birth was not significantly different between treatment groups (404 [34%] in the folic acid and zinc group and 416 [35%] in the placebo group; risk difference, -0.9% [95% CI, -4.7% to 2.8%]). Most of the semen quality parameters (sperm concentration, motility, morphology, volume, and total motile sperm count) were not significantly different between treatment groups at 6 months after randomization. A statistically significant increase in DNA fragmentation was observed with folic acid and zinc supplementation (mean of 29.7% for percentage of DNA fragmentation in the folic acid and zinc group and 27.2% in the placebo group; mean difference, 2.4% [95% CI, 0.5% to 4.4%]). Gastrointestinal symptoms were more common with folic acid and zinc supplementation compared with placebo (abdominal discomfort or pain: 66 [6%] vs 40 [3%], respectively; nausea: 50 [4%] vs 24 [2%]; and vomiting: 32 [3%] vs 17 [1%]).

CONCLUSIONS AND RELEVANCE:
Among a general population of couples seeking infertility treatment, the use of folic acid and zinc supplementation by male partners, compared with placebo, did not significantly improve semen quality or couples’ live birth rates. These findings do not support the use of folic acid and zinc supplementation by male partners in the treatment of infertility.

TRIAL REGISTRATION:
ClinicalTrials.gov Identifier: NCT01857310.

Title

Effect of Folic Acid and Zinc Supplementation in Men on Semen Quality and Live Birth Among Couples Undergoing Infertility Treatment: A Randomized Clinical Trial.

Author

Schisterman EF1, Sjaarda LA1, Clemons T2, Carrell DT3, Perkins NJ1, Johnstone E4, Lamb D4, Chaney K2, Van Voorhis BJ5, Ryan G5, Summers K5, Hotaling J6, Robins J7, Mills JL1, Mendola P1, Chen Z8, DeVilbiss EA1, Peterson CM4, Mumford SL1.

Publish date

2020 Jan 7

PMID

31874034

Abstract

Folic acid, a synthetic form of folate, is a water-soluble vitamin that is essential during periods of rapid cell division and growth. However, it decomposes upon ultraviolet irradiation to form inactive photoproducts. In this study, the protective effect and mechanisms of antioxidants, including cinnamic acids, flavonoids, catechol and its derivatives, stilbenes, p-benzoquinone and its derivatives, isoprenoids, curcumin, oleic acid, and linoleic acid, against folic acid photodecomposition were investigated by using fluorescence and absorbance spectroscopy, high-performance liquid chromatography, and antioxidant assay. It was found that antioxidants could inhibit or delay the folic acid decomposition in varying degrees, among which caffeic acid was the most effective. The increase in its remarkable antioxidant efficiency and absorbance in the UVA region during irradiation contributed to its effective protection. This finding could be useful for the protection of photolabile components in food and other uses.

KEYWORDS

antioxidant; folic acid; inhibition; photodecomposition

Title

Mechanism for Inhibition of Folic Acid Photodecomposition by Various Antioxidants.

Author

Wusigale, Hu L, Cheng H, Gao Y, Liang L.

Publish date

2020 Jan 8


Description :

Folic acid(Vitamin M; Vitamin B9) is a B vitamin; is necessary for the production and maintenance of new cells, for DNA synthesis and RNA synthesis.